{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T20:21:14Z","timestamp":1779913274801,"version":"3.53.1"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/spy6bza1h6qc","name":"Masarykova Univerzita","doi-asserted-by":"publisher","award":["project MUNI\/A\/1433\/2023"],"award-info":[{"award-number":["project MUNI\/A\/1433\/2023"]}],"id":[{"id":"10.13039\/spy6bza1h6qc","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/spbpod4xp2zd","name":"Ministerstvo Vnitra Ceske Republiky","doi-asserted-by":"publisher","award":["FNBr, 65269705"],"award-info":[{"award-number":["FNBr, 65269705"]}],"id":[{"id":"10.13039\/spbpod4xp2zd","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n          <jats:p>Acute exacerbations of cystic fibrosis (CF) diminish quality of life and, if inadequately treated, can be life-threatening. The pathophysiological alterations associated with CF result in modified antibiotic pharmacokinetics. Moreover, the viscous mucus in the lungs limits pathogen exposure to drugs, rendering successful antibiotic treatment challenging. A 23-year-old female patient with CF was repeatedly admitted for intravenous antibiotic therapy for acute exacerbation of <jats:italic toggle=\"yes\">Pseudomonas aeruginosa<\/jats:italic> infection. In the context of altered pharmacokinetics in CF, therapeutic drug monitoring of meropenem and piperacillin revealed consistently low plasma levels of both drugs. Targeted plasma levels were ultimately achieved through continuous high-dose infusions, based on therapeutic drug monitoring and subsequent dose adjustments.<\/jats:p>","DOI":"10.1097\/ftd.0000000000001340","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T14:01:39Z","timestamp":1747836099000},"page":"580-583","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Therapeutic Drug Monitoring of Beta-Lactams in Cystic Fibrosis: Unattained Target in Standard Antibiotic Dosing"],"prefix":"10.1097","volume":"47","author":[{"given":"Eliska","family":"Maraczek Markova","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, Hospital Pharmacy, University Hospital Brno, Brno, Czech Republic;"},{"name":"Department of Pharmacology and Toxicology, Faculty of Pharmacy, Masaryk University Brno, Brno, Czech Republic;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6906-9901","authenticated-orcid":false,"given":"Nela","family":"Stastna","sequence":"additional","affiliation":[{"name":"Department of Pneumology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic; and"},{"name":"Faculty of Medicine, Masaryk University Brno, Brno, Czech Republic."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Libor","family":"Fila","sequence":"additional","affiliation":[{"name":"Department of Pneumology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina","family":"Horska","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Hospital Pharmacy, University Hospital Brno, Brno, Czech Republic;"},{"name":"Department of Pharmacology and Toxicology, Faculty of Pharmacy, Masaryk University Brno, Brno, Czech Republic;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,5,21]]},"reference":[{"key":"R1-20250912","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1007\/s40265-021-01635-6","article-title":"The epidemiology and pathogenesis and treatment of Pseudomonas aeruginosa infections: an update","volume":"81","author":"Reynolds","year":"2021","journal-title":"Drugs"},{"key":"R3-20250912","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.3390\/antibiotics12091388","article-title":"Pharmacokinetic\/pharmacodynamic target attainment of continuous infusion Piperacillin\u2013Tazobactam or Meropenem and microbiological outcome among urologic patients with documented Gram-Negative infections","volume":"12","author":"Berrino","year":"2023","journal-title":"Antibiotics"},{"key":"R4-20250912","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.3390\/antibiotics10111311","article-title":"Assessment of a PK\/PD target of continuous infusion beta-lactams useful for preventing microbiological failure and\/or resistance development in critically ill patients affected by documented Gram-Negative infections","volume":"10","author":"Gatti","year":"2021","journal-title":"Antibiotics"},{"key":"R5-20250912","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.3390\/antibiotics10101154","article-title":"Beta-lactams dosing in critically ill patients with Gram-Negative bacterial infections: a PK\/PD approach","volume":"10","author":"Maguigan","year":"2021","journal-title":"Antibiotics"},{"key":"R6-20250912","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40262-021-01061-7","article-title":"Penetration of antibacterial agents into pulmonary epithelial lining fluid: an update","volume":"61","author":"Drwiega","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"R8-20250912","doi-asserted-by":"crossref","first-page":"568","DOI":"10.3390\/antibiotics12030568","article-title":"Update on therapeutic drug monitoring of beta-lactam antibiotics in critically ill patients\u2014a narrative review","volume":"12","author":"Sta\u0161ek","year":"2023","journal-title":"Antibiotics"},{"key":"R10-20250912","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1093\/ajhp\/zxaa128","article-title":"Towards precision medicine: therapeutic drug monitoring\u2013guided dosing of vancomycin and \u03b2-lactam antibiotics to maximize effectiveness and minimize toxicity","volume":"77","author":"Cusumano","year":"2020","journal-title":"Am J Health Syst Pharm"},{"key":"R11-20250912","doi-asserted-by":"crossref","first-page":"e00654-17","DOI":"10.1128\/AAC.00654-17","article-title":"Neurotoxic concentration of piperacillin during continuous infusion in critically ill patients","volume":"61","author":"Quinton","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"R12-20250912","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1080\/17425255.2021.1836157","article-title":"The pharmacokinetics of antibiotics in cystic fibrosis","volume":"17","author":"Akkerman-Nijland","year":"2021","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R13-20250912","doi-asserted-by":"crossref","first-page":"106381","DOI":"10.1016\/j.ijantimicag.2021.106381","article-title":"Pharmacokinetics and pharmacodynamics of antibiotics in cystic fibrosis: a narrative review","volume":"58","author":"Castagnola","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"R14-20250912","doi-asserted-by":"crossref","first-page":"107237","DOI":"10.1016\/j.rmed.2023.107237","article-title":"Therapeutic drug monitoring in cystic fibrosis and associations with pulmonary exacerbations and lung function","volume":"212","author":"Katz","year":"2023","journal-title":"Respir Med"},{"key":"R15-20250912","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s40262-020-00981-0","article-title":"Pharmacokinetic and pharmacodynamic optimization of antibiotic therapy in cystic fibrosis patients: current evidences, gaps in knowledge and future directions","volume":"60","author":"Magr\u00e9ault","year":"2021","journal-title":"Clin Pharmacokinet"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001340","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T12:02:06Z","timestamp":1757678526000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,21]]},"references-count":12,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001340","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,21]]},"assertion":[{"value":"2024-12-02","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-01","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}